Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients

BACKGROUND: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatas...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Bone Oncol
Hoofdauteurs: Göbel, Andy, Kuhlmann, Jan D., Link, Theresa, Wimberger, Pauline, Link-Rachner, Cornelia, Thiele, Stefanie, Dell'Endice, Stefania, Furesi, Giulia, Breining, Dorit, Rauner, Martina, Hofbauer, Lorenz C., Rachner, Tilman D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2019
Onderwerpen:
Short Communication
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461588/
https://ncbi.nlm.nih.gov/pubmed/31011525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2019.100237
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items